Sirus Overview

  • Founded
  • 1992
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Sirus General Information

Description

Operator of a pharmaceutical research company. The company focuses on drug development for the treatment of nerve injury and muscle spasm by using its proprietary platform technologies that covers pain, emesis, epilepsy and insomnia.

Contact Information

Formerly Known As
SynGenix
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Delivery
Drug Discovery
Acquirer
Primary Office
  • Babraham Hall
  • Babraham
  • Cambridge CB2 4AT
  • England, United Kingdom
+44 01223 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sirus Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 01-Mar-2004 00.00 Completed Generating Revenue
2. Later Stage VC 11-Sep-2001 00.000 00.00 Completed Generating Revenue
1. Later Stage VC 01-Jan-1998 $2.49M $2.49M Completed Generating Revenue
To view Sirus’s complete valuation and funding history, request access »

Sirus Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cambridge Research and Innovation Venture Capital Minority 000 0000 000000 0
Providence Investment Management Asset Manager Minority 000 0000 000000 0
Science Group Corporation Minority 000 0000 000000 0
Technomark Medical Ventures Venture Capital Minority 000 0000 000000 0
World Life Sciences Other Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »